UK markets open in 5 hours 17 minutes

IMMX May 2024 2.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.0500-1.2000 (-96.00%)
As of 12:06PM EDT. Market open.
Full screen
Previous close1.2500
Open0.0500
Bid0.0000
Ask0.5500
Strike2.50
Expiry date2024-05-17
Day's range0.0500 - 0.0500
Contract rangeN/A
Volume10
Open interest10
  • GlobeNewswire

    Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation

    92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of which 9 out of 12 were complete responders (75% CRs) 1 patient with prior exposure to BCMA-targeted bispecific treatment did not respond Best responder duration of response was 28.0 months with response ongoing as of May 10, 2024U.S. prevalence of relapsed/refractory AL Amyloidosis i

  • GlobeNewswire

    Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma

    European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for: EU protocol assistance, marketing authorization applications, inspections before authorization, applications for changes to marketing authorizations made after approval, and reduced annual fees LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, N

  • GlobeNewswire

    Immix Biopharma on Track to Dose NXC-201 Patients in United States

    Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024 No change in patient enrollment timing LOS ANGELES, April 18, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today